glp 1 nejm SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants This NEJM Perspective highlights a

glp 1 nejm

glp 1 nejm SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants This NEJM Perspective highlights a

Name: glp 1 nejm SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants This NEJM Perspective highlights a
Brand: neboallen.info
SKU: 48665174687
Price: 29.32 USD
Availability: InStock
Rating: 4.8649 (22 reviews)

SKU: 48665174687

4.9

EUR29.32 EUR56.32

Pay in 4 interest-free payments of $7.33 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 22 - Aug 27

Description

Mutant KRAS induces the monocyte to become the tumor-promoting phenotype (M2 type) through secreting many factors to elicit polarization in macrophages (Song et al., 2016)